BNT111 is a key part of the German biotech's pipeline and development strategy as it responds to declining sales of its Pfizer-partnered COVID-19 vaccines ... and Daiichi Sankyo's Enhertu.

Targeting more than one viral protein has shown in the recent past to be effective: one of the mRNA COVID-19 shots was a bivalent vaccine that worked against two different strains of the virus.

Researchers at the National Institutes of Health (NIH) have started dosing patients in a phase 1 trial of a new influenza vaccine candidate ... of AstraZeneca and Daiichi Sankyo's Enhertu.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) gave its thumbs-up to eight new medicines including two vaccines ... and Daiichii Sankyo’s antibody-drug ...

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...

TOKYO & BASKING RIDGE, N.J., January 13, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property ...